CervoMed Inc. 8-K

What Happened

• CervoMed, Inc. filed Form 8-K on April 22, 2026, disclosing a press release (Exhibit 99.1) and presentation materials reporting data from its Phase 2b RewinD-LB trial presented at the 2026 American Academy of Neurology (AAN) Annual Meeting. The company reported that neflamapimod increased basal forebrain volume and functional connectivity in patients with dementia with Lewy bodies (DLB). The company posted related presentation materials on its investor website under “Investors – Events and Presentations.”

Key Details

• Filing date: April 22, 2026 (Form 8-K; press release attached as Exhibit 99.1).
• Trial: Phase 2b RewinD-LB; data presented at the 2026 AAN Annual Meeting.
• Primary reported finding: neflamapimod increased basal forebrain volume and functional connectivity in DLB patients.
• Company notes presentation materials may be used in investor/analyst meetings and is available on cervomed.com; no obligation to update except as required by law.

Why It Matters

• These Phase 2b clinical data show a measurable biological effect of neflamapimod in DLB patients, a key proof point for the program’s development pathway. For investors, the results may influence perceptions of CervoMed’s clinical progress and potential value of its neurology pipeline. The filing is informational—next steps, regulatory implications, or commercial impact were not detailed in the 8-K and will depend on future disclosures.